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Abstract
Purpose: To evaluate the outcomes of ruthenium-106 (106Ru) brachytherapy in terms of radiation parameters in 
patients with thick uveal melanomas.
Material and methods: Medical records of 51 patients with thick (thickness ≥ 7 mm and < 11 mm) uveal melanoma 
treated with 106Ru brachytherapy during a ten-year period were reviewed. Radiation parameters, tumor regression, 
best corrected visual acuity (BCVA), and treatment-related complications were assessed.
Results: Fifty one eyes of 51 consecutive patients including 25 men and 26 women with a mean age of 50.5 ± 15.2 
years were enrolled. Patients were followed for 36.1 ± 26.5 months (mean ± SD). Mean radiation dose to tumor apex 
and to sclera were 71 (± 19.2) Gy and 1269 (± 168.2) Gy. Radiation dose rates to tumor apex and to sclera were 0.37 
(± 0.14) Gy/h and 6.44 (± 1.50) Gy/h. Globe preservation was achieved in 82.4%. Preoperative mean tumor thickness of 
8.1 (± 0.9) mm decreased to 4.5 (± 1.6) mm, 3.4 (± 1.4) mm, and 3.0 (± 1.46) mm at 12, 24, and 48 months after brachyther-
apy (p = 0.03). Four eyes that did not show regression after 6 months of brachytherapy were enucleated. Secondary 
enucleation was performed in 5 eyes because of tumor recurrence or neovascular glaucoma. Tumor recurrence was 
evident in 6 (11.8%) patients. Mean Log MAR (magnification requirement) visual acuity declined from 0.75 (± 0.63) to 
0.94 (± 0.5) (p = 0.04). Best corrected visual acuity of 20/200 or worse was recorded in 37% of the patients at the time 
of diagnosis and 61.7% of the patients at last exam (p = 0.04). Non-proliferative and proliferative radiation-induced 
retinopathy was observed in 20 and 7 eyes.
Conclusions: Thick uveal melanomas are amenable to 106Ru brachytherapy with less than recommended apex 
radiation dose and dose rates.
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Purpose
Uveal melanoma (UM) is the most common primary 
malignant intraocular tumor in adults [1]. It is a life and 
sight threatening malignancy that is treatable if diag-
nosed in time and treated appropriately. The treatment 
modality of choice is mostly determined by the size and 
the location of the tumor. While small and medium sized 
UMs can be successfully treated with a variety of meth-
ods, no consensus exists about the optimum management 
for thick (≥ 7 mm) UMs [2,3,4]. Enucleation has tradition-
ally been the treatment of choice for the majority of large 
UMs [5], however, in certain situations such as the pres-
ence of a tumor in the only remaining eye, poor vision in 
the fellow eye, or whenever a patient insists on avoiding 
enucleation, conservative treatment modalities aimed 
at preserving the diseased eye can be considered [3]. 
Although improving patient survival has been claimed 
as the most important rationale to support enucleation 
as the standard of care for large UM, the Collaborative 
Ocular Melanoma Study (COMS) results (report No 28) 
as well as publications by independent groups show that 
different treatment options, either conservative or radical 
(enucleation), are not associated with a definitive survival 
benefit [6,7,8,9]. This is one of the reasons that enucleation 
has been largely replaced by conservative modalities such 
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as brachytherapy, proton beam radiation, stereotactic 
radiotherapy, and tumor resection in recent years [4,5]. 
Of these, ruthenium-106 (106Ru) brachytherapy is one of 
the most commonly used treatments [10].
Localized radiation therapy of UM by 106Ru plaques 
has been the treatment of choice particularly in Europe 
for medium sized UMs since its introduction in the 1960s 
[11]. 106Ru emits a spectrum of β-particles that, compared 
to gamma-radiation of 125I plaques, imposes lower un-
toward radiation to nontumoral eye structures such as 
the optic disc, macula, and lens. A major concern for the 
use of 106Ru plaques is its steep dose gradient in large 
tumors, meaning that the radiation dose falloff is quick, 
and in large UMs, the apex dose may not reach the rec-
ommended dose of 85 Gy [11]. Thus, some authors be-
lieve that 106Ru plaques are not suitable for tumors with 
a thickness of 7 mm or more because the high dose to 
the outer sclera is a concern [12,13,14]. In contrast, multi-
ple clinical studies have shown that 106Ru brachytherapy 
can result in a favorable clinical outcome and complete 
regression even in large tumors [15,16]. Thus, more data 
is needed to determine the UM thickness limit and the 
optimum radiation dose for 106Ru plaque application.
Herein, we report the functional and anatomical out-
comes of 106Ru brachytherapy for thick UM with focus on 
prescribed apex and base radiation dose and dose rate.
Material and methods
Using a historical cohort design, we reviewed the clin-
ical data from all patients with a diagnosis of UM who 
were treated with 106Ru plaques at the Ocular Oncolo-
gy Services of Rassoul Akram Hospital, Iran University 
of Medical Sciences, Tehran, Iran and Noor Eye Hospi-
tal, Tehran, Iran between October 2002 and March 2013. 
Fifty one consecutive patients with the diagnosis of thick 
choroidal or ciliochoroidal melanoma (7 mm ≤ thickness 
< 11 mm) with no history of distant metastasis who were 
treated by 106Ru brachytherapy were included in this 
study. Patients with less than 12 months follow-up were 
excluded. Chart data included patient demographics, best 
corrected visual acuity (BCVA), slit-lamp, and fundus ex-
amination findings including tumor location, pigmenta-
tion, distance between the posterior border of the tumor 
and fovea and optic disc, the presence of retinal inva-
sion, and the presence of subretinal fluid at initial exam. 
The largest basal diameter and apical height at initial and 
follow-up examinations were recorded by an experienced 
ophthalmic ultrasonographer. The tumor size was mea-
sured on ultrasound images; clinical target volume (CTV) 
was determined as basal tumor diameter plus a 2 mm 
safety margin and an extra 1 mm on tumor height to ac-
count for scleral thickness. Calibration of the plaques was 
done in a homemade Perspex eye phantom in orthogo-
nal planes perpendicular to the central axis of the plaques 
using Gafchromic EBT2 film (ISP, Wayne, NJ, USA) [17]. 
The manufacturer’s specifications on point dose levels in 
water were measured. Isodose planes perpendicular and 
parallel to the applicator central axis were determined 
and used to evaluate the CTV coverage. The size of the 
eye plaques was determined to be at least 3 mm larger 
than the tumor basal diameter to account for inactive rim 
and safety margin. Three plaques, namely CCB, CGD, and 
COB were used. At the time of the treatment, the plaques’ 
dose rate was corrected based on 106Ru decay factor and 
the time since its manufacture.
Corrected apical dose rate at the day of application (Gy/h) =
Apical dose rate at the time of plaque construction (mGy/min)  
× decay factor × 60
1000
To calculate the overall treatment time, the apical dose 
covering the CTV thickness (prescription dose) is divided 
by the corrected apical dose rate at the time of surgery.
Overall treatment (h) = 
Total prescribed dose (Gy)
                                     Dose rate (Gy/h)
In few instances where scleral maximum dose could 
surpass the 1500 Gy limit, implementation time was 
calculated differently, i.e. the scleral tolerance dose of 
1500 Gy was divided by dose rate at a point 0.6 mm dis-
tant from the surface of the plaque. As such, the apical 
dose could be less than the recommended 100 Gy for 
uveal melanomas [18]. 
Radiation parameters (plaque shape and size, total 
radiation dose to apex and base, radiation dose rate for 
apex and base, and duration of radiation) were docu-
mented. Complications such as radiation related retino-
pathy and papillopathy, cataract, vitreous hemorrhage, 
neovascular glaucoma (NVG), and scleral necrosis were 
noted. The treatment protocol in both centers required us 
to offer enucleation as the first and standard treatment 
modality for all patients with UM equal to or larger than 
7 mm in thickness. Patients who rejected enucleation were 
considered for 106Ru brachytherapy. The off-label use of 
106Ru brachytherapy for a tumor height ≥ 7 mm and the 
safety concerns were discussed extensively with the pa-
tient and family, and an informed consent was obtained. 
Patients with a tumor height ≥ 11 mm, any evidence of 
large extraocular extension (> 3 mm in largest diameter), 
systemic metastasis of the tumor, and a history of prior 
treatment for UM were not considered for brachytherapy. 
Tumor thickness and tumor diameters were measured by 
standardized A-scan and B-scan ultrasonography (Aviso, 
Quantel Medical SA, Le Brezet, France). A comprehen-
sive systemic workup including physical examination, 
liver enzyme tests, liver ultrasound and abdominal CT 
scan (if needed), and chest X-ray were performed for all 
patients to rule out the possibility of distant metastasis. 
The study was approved by the Ethics Committee of the 
Eye Research Center at Rassoul Akram Hospital and 
Noor Eye Hospital.
Surgical procedure
All surgeries were performed under general anes-
thesia by one surgeon (MNP). Tumor outlines over the 
sclera were identified by intraoperative transillumina-
tion for pigmented tumors and indirect ophthalmoscopy 
for non-pigmented tumors. Acrylic dummies checked 
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tumor location before selecting and suturing the radio-
active plaque. Extraocular muscles were temporarily 
disinserted by hang-back suture if needed. 106Ru plaques 
were supplied by BEBIG Company (BEBIG Isotopen und 
Medizintechnik GmbH, Berlin, Germany) in different 
shapes and sizes. The target radiation dose for the tumor 
apex was 100 Gy provided that the scleral doses did not 
exceed 1500 Gy. The dose rate correction has been ap-
plied for different dose rates [19]. We included a lateral 
safety margin of 2 mm around the tumor base [20]. Using 
5-0 Mersilene sutures, plaques were secured to the sclera 
for the duration of calculated radiation time. The plaque 
was removed, and conjunctiva was sutured with 7-0 Vic-
ryl sutures at the end of the radiation period. After initial 
biweekly visits for four weeks, patients were followed 
every 3 months during the first year after surgery, every 
4 months up to 2 years, and every 6 months thereafter. 
The follow-up examinations included BCVA, slit lamp 
biomicroscopy, dilated fundus examination, applanation 
tonometry, and A- and B-scan ultrasonography. Color 
fundus photography, OCT, and fluorescein angiography 
were performed if any evidence of proliferative radiation 
retinopathy was suspected. Liver enzymes were checked 
and a liver ultrasound was performed every 6 months. 
A chest x-ray was obtained annually for all patients. 
Transpupillary thermotherapy was performed using 
a commercial 810 nm laser (Iris Medical, Instruments, Inc. 
Mountain, CA, USA) as an adjuvant therapy in patients 
with insufficient reduction in thickness at least 6 months 
after 106Ru brachytherapy.
Analysis of data was done using SPSS version of 20.0 
(SPSS Inc., Chicago, Il, USA). Paired t-test was used to com-
pare changes of numeric variables during follow-up times. 
We used univariate analyses and estimated crude hazard 
risks using Cox proportional hazard model. The study 
endpoints of globe preservation, visual outcome, and radi-
ation induced complications were entered in multivariate 
Cox proportional hazard models to estimate the adjusted 
hazard risks (AHR). Time-to-event analyses for patients 
free of enucleation, tumor recurrence, and complications 
were assessed using Kaplan-Meier estimate. In these anal-
ysis, each endpoint entered separately and for each end-
point, if at the end of follow-up the event did not occurred, 
or the patient was dropped out of the study due to any rea-
son during the follow-up, considered as “censored”. A sta-
tistically significant level was defined at ≤ 0.05.
Results
Fifty one eyes of 51 patients with thick uveal mela-
noma including 25 men and 26 women with a mean 
(± SD) age of 50.5 (± 15.2) years (range: 17-84 years) were 
treated with 106Ru brachytherapy. Patients were fol-
lowed for a median time of 29.5 months (mean ± SD: 36.1 
± 26.5 months, range: 12-112 months). Table 1 shows pa-
tient demographic data and tumor characteristics.
The mean prescription dose to the apex and sclera 
was 71 Gy (range: 31-104 Gy) and 1269 Gy (range: 809-
1560 Gy), respectively. The mean radiation dose rate at the 
tumor apex and sclera was 0.37 Gy/h (range: 0.13-0.79) 
and 6.44 Gy/h (range: 3.75-9.34), correspondingly. Gen-
erally, because of the scleral limit of 1500 Gy, 33.3% of 
patients received an apex dose less than 60 Gy, 29.4% re-
ceived a dose between 60 and 80 Gy, and 37.3% received 
a dose more than 80 Gy. Regarding the base dose, all of 
the tumors have been irradiated with a dose more than 
800 Gy (mean dose of 1269 Gy) and 48 eyes (94%) have 
been irradiated more than 1000 Gy. Table 2 shows dosim-
etric characteristics of this 51 patients.
The total number of patients for calculation were 
47, 45, and 40 at 12, 24, and 48 months after treatment. 
Two patients had not thickness examinations at 48 month 
follow-up. Preoperative average tumor thickness of 8.1 
± 0.9 mm decreased to 4.5 (± 1.6), 3.4 (± 1.4), and 3.0 
(± 1.46) mm at 12, 24, and 48 months after brachytherapy, 
respectively.
Table 1. Demographics and tumor characteristics 
of 51 patients with thick uveal melanoma (thick-
ness ≥ 7 mm)
Features Values
Number 51
Age (years); median (mean, range) 48 (50.5, 17-84)
Gender (male, female) (25, 26) (49%, 51%)
Medical history
None 40 (78.43%)
Diabetes mellitus 3 (5.88%)
Hypertension 8 (15.69%)
Eye
Right, left 22, 29 (43.1%, 56.9%)
Tumor
Choroidal melanoma 42 (82.35%)
Ciliochoroidal melanoma 9 (17.65%)
Tumor dimensions (mm)
Base 1 (min, max, mean, median) (7.00, 19.00, 13.83, 14.00)
Base 2 (min, max, mean, median) (6.00, 18.00, 12.20, 12.00)
Thickness (min, max, mean, median) (7.00, 10.50, 8.12, 8.00)
Shape
Dome shaped 38 (74.5%)
Mushroom shaped 13 (25.5%)
Subretinal fluid
Yes 39 (76.5%)
No 12 (23.5%)
Distance to optic disc (mm); median 
(mean, range)
3.00 (3.92, 0.00-13.00)
Distance to foveola (mm); median 
(mean, range)
3.00 (3.85, 0.00-11.00)
Overhanging on the disc
0 46 (90.20%)
< 50% 4 (7.84%)
≥ 50% 1 (1.96%)
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Evidence of regression was not seen in 4 eyes (7.8%) 
during the first 6 months of brachytherapy, so early enu-
cleation was performed. In these patients, the average tu-
mor thickness was 8.9 mm and mean apical and scleral 
radiation dose was 55.3 and 1337 Gy, respectively.
Secondary enucleation was done in an additional 
5 (9.8%) eyes due to the recurrence of the tumor or due 
to neovascular glaucoma development. The median time 
to late enucleation was 31 (range: 12-71) months. Based 
on Kaplan-Meier estimates, enucleation was essential in 
13.7% and 17.6% of patients at 5 and 10 years follow-up, 
respectively (Table 3).
The overall anatomical success rate (preserving the 
eye) was 82.4% (42 out of 51 cases) in our study. Recur-
rence of tumor in 6 patients in this study was managed 
with enucleation in 3 patients, transpupillary thermother-
apy in one patient, and secondary 106Ru plaque insertion 
in two other patients. Enucleation was indicated in two 
patients with severe post-treatment tumor necrosis and 
extensive intraocular hemorrhage 38 and 25 months after 
brachytherapy. Kaplan–Meier survival analysis showed 
11.8% and 13.7% tumor recurrence at 5 and 10 years, re-
spectively (Table 3). The median time to recurrence was 
12 (range 2-71) months.
Factors predicting enucleation, poor visual acuity 
(VA less than 20/200), and tumor recurrence are listed in 
Table 4. Although in the univariate model, the history of 
hypertension, tumor overhanging on optic nerve head, 
notched plaque shape, and radiation hours were predictors 
of enucleation (p < 0.05), in multivariate analysis, the only 
predictor of enucleation was past medical history of hy-
pertension. (Cox proportional hazard estimate, HR = 3.60, 
p = 0.02). Since in bi-variate analyses, the radiation hours 
was significant – not the radiation dose, so we just en-
tered the radiation hours factor in multivariate analyses. 
The location of recurrence was at the margin in 3 (5.8%) 
eyes and at the center in 4 (7.8%) tumors. History of 
hyper tension and notched plaque shape were predictors 
for tumor recurrence in univariate analysis.
Preoperative BCVA (mean ± SD) of 0.75 ± 0.63 Log 
MAR dropped to 0.94 ± 0.50 at last follow-up (p = 0.04). 
Thirty-seven percent (12 eyes) of the patients at the time 
of diagnosis and 61.7% (29 eyes) of the patients at last 
exam had BCVA of 20/200 or worse (p = 0.04). Using 
Table 2. Dosimetric characteristics of 106Ru plaque treatment of 51 patients with thick choroidal and ciliocho-
roidal melanoma and two subgroup of patients with and without recurrent lesions
Parameter 51 patients 45 patients without 
recurrence
6 patients with 
recurrence
Radiation hours (range, mean, median) 101-314, 209, 215 101-314, 210, 215 135-281, 211, 212
Apex dose rate (Gy/h) (range, mean, median) 0.13-0.79, 0.37, 0.37 0.13-0.79, 0.36, 0.34 0.2-0.6, 0.36, 0.33
Apex dose (Gy) (range, mean, median) 31-104, 71, 74 31-104, 71.4, 74.3 40-93.5, 69, 73
Scleral dose rate (Gy/h) (range, mean, median) 3.8-9.3, 6.4, 6.0 3.7-9.3, 6.4, 6.1 5-9, 6.3, 5.6
Scleral dose (Gy) (range, mean, median) 809-1560, 1269, 1306 809-1560, 1277, 1341 1105-1350, 1232, 1243
Table 3. Kaplan-Meier analyses estimate the likelihood of developing poor final outcome at 2, 5, and 10 years 
of follow-up after 106Ru plaques radiotherapy
Outcomes At 2 years 
(n, %)
At 5 years 
(n, %)
At 10 years 
(n, %)
Poor visual acuity (20/200 or worse) 15, 31.9% 27, 57.4% 29, 61.7%
Complications
Retinopathy
Proliferative 5, 10.6% 6, 12.8% 7, 13.7%
Non-proliferative 13, 25.5% 19, 37.2% 20, 39.2%
Maculopathy 8, 15.7% 10, 19.6% 10, 19.6%
Papillopathy 9, 19.1% 15, 31.9% 15, 31.9%
Cataract 15, 31.9% 18, 38.3% 19, 40.4%
Neovascular glaucoma 2, 3.9% 2, 3.9% 3, 5.9%
Vitreous hemorrhage 5, 9.8% 8, 15.7% 9, 17.6%
Enucleation 6, 11.8% 7, 13.7% 9, 17.6%
Tumor recurrence 5, 9.8% 6, 11.8% 7, 13.7%
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Kaplan-Meier estimates, poor visual acuity (VA ≤ 20/200) 
was evident in 31.9% and 57.4% of the cases at 2 and 
5 years follow-up, respectively (Table 3). Mushroom- 
shaped tumor and a less than 3 mm distance to optic nerve 
were significant predictors of poor visual acuity (Table 4).
Adjuvant transpupillary thermotherapy was perform-
ed in 9 (19.4%) eyes. Tumor related metastasis was ob-
served in 3 (5.9%) patients, and one of these patients died 
of liver metastasis during the follow-up time.
Non-proliferative radiation retinopathy was observed 
in 20 eyes (39.2%) and proliferative retinopathy in 7 other 
eyes (13.7%). Of all patients who had radiation retino-
pathy (proliferative and non-proliferative), macular in-
volvement was evident in 10 (19.6%) patients. Vitreous 
hemorrhage developed in 9 eyes (17.6%) after treatment. 
Non-clearing vitreous hemorrhage in 5 eyes (9.8%) was 
successfully managed with parsplana vitrectomy. Radia-
tion papillopathy and cataract progression was detected 
in 15 eyes (29.4%) and 19 eyes (37.2%), respectively. Pre-
dictors of radiation maculopathy, radiation papillopathy, 
and radiation retinopathy are summarized in Table 5. 
All predictors had significant effects on radiation compli-
cations in univariate analysis. We were not able to show 
any significant effects after adjusting these variables in 
multivariate analysis.
Postoperative temporary increase in subretinal fluid 
(SRF) was managed conservatively in all except one pa-
tient who was monocular and experienced bullous, exu-
dative retinal detachment followed by neovascularization 
of the iris (NVI) during the first month after brachythera-
py. Because of the absence of response to oral corticoste-
roids, parsplana vitrectomy with endolaser photocoagu-
lation and silicone oil tamponade was performed for this 
patient. Postoperative NVI was managed with an intrav-
itreal bevacizumab injection in 4 (7.8%) patients.
Discussion
Identification of a cut-off point as an optimal height 
for each isotope to manage the uveal melanoma with 
brachytherapy and avoid of enucleation is still unre-
solved issue.
Although based on the COMS recommendation [21] tu-
mors, up to 10 mm can be treated with 125I brachy therapy, 
published studies from European countries [14,22,23] in-
dicate that 106Ru radioactive plaques is a choice of treat-
ment for uveal melanomas with tumor height of 5.4 to 
7 mm because of its limited depth of penetration. There-
fore, the cut-off point of 7 mm was considered for thick 
tumor implication and inclusion criterion in our study.
Our study showed that 106Ru brachytherapy in select-
ed eyes with thick uveal malignant melanomas (7 mm 
≤ thickness < 11 mm) that would otherwise be managed 
with enucleation could result in a high local tumor con-
trol rate in spite of the less than recommended radiation 
dose and dose rate to the apex in the majority of our cases.
Enucleation with or without pretreatment radiation is 
classically recommended for UM thicker than 7 mm [24]. 
Alternative treatments include brachytherapy [14,25,26], 
gamma-knife radiosurgery [27], proton beam radiation 
[28,29], fractionated stereotactic radiotherapy [30,31], and 
partial lamellar sclerouvectomy [32]. However, none of 
these alternative therapies has been evaluated prospec-
tively.
Published data regarding the impact of brachythera-
py on UM generally support two schools of thought [33]. 
Some studies emphasize achieving 85 Gy of radiation to 
the tumor apex [16], provided no more than 1000 Gy is 
applied to the sclera [33]. Based on this concept, the tumor 
apex should receive enough of a tumoricidal radiation 
dose to kill the tumor cells directly. Others believe that 
Table 4. Predictors of enucleation, tumor recurrence, and poor visual acuity in 51 patients with thick choroidal 
melanoma (7 mm ≤ thickness < 11 mm) after 106Ru brachytherapy (poor visual acuity was defined as VA less 
than or equal to 20/200)
Variable p value Hazard ratio 95% confidence interval
Enucleation predictors
History statusa 0.037 11.12 1.160-107.889
Tumor overhanging on optic nerveb 0.022 5.35 1.160-22.493
Plaque shapec 0.004 10.83 2.180-53.845
Radiation hoursd 0.046 1.02 1.000-1.032
Tumor recurrence predictors
History statusa 0.012 8.74 1.595-47.923
Plaque shapec 0.005 3.37 1.109-11.294
Poor visual acuity predictors
Tumor shapee 0.022 2.45 1.138-5.258
Distance to optic nervef 0.035 0.45 0.214-0.944
Plaque shapec 0.005 2.81 1.356-5.831
aHypertension present or absent, bpresent vs. absent, cCOB vs. CCB vs. CGD, dmean radiation hours, emushroom vs. dome-shaped, fless than vs. ≥ 3 mm
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indirect tumoricidal effects of radiation through obliter-
ating tumor blood supply can justify lower doses to apex 
even when the tumor is very thick, and the apex of tumor 
will receive radiation less than the recommended dose 
[15,16,34]. Compatible with this theory, some authors 
[22] have recommended a minimal radiation dose of 300- 
400 Gy to the sclera for development of choroidal atrophy.
Our results showed 82.4% globe preservation with an 
average 106Ru radiation dose of 71 Gy to the apex. This 
is similar to Kaiserman et al. [15] report, which indicat-
ed 71.4% globe preservation in patients with thick UM 
(≥ 8 mm in thickness) treated with 106Ru brachytherapy at 
mean apex dose of 69.9 Gy.
Radiation complications are major causes of visual 
loss after brachytherapy. One of the most important ap-
proaches to reduce radiation complications secondary 
to brachytherapy is to prescribe a less than convention-
al therapeutic dose of 85 Gy to the tumor apex, without 
compromising local tumor control. In a retrospective re-
view of 62 patients treated with 125I plaque brachythera-
py for choroidal melanoma, Saconn et al. [35] prescribed 
a lower dose of radiation to the apex. Although the mean 
apex dose was reduced to 62.5 Gy, the 5-year enucleation 
rate was 12.0%, which is comparable to the 13.7% enucle-
ation rate at 5 years in our study with the mean apex dose 
of 71 Gy (median 73.6 Gy).
Our results are also similar to those reported by 
Shields et al. [26] who reported a 24% enucleation rate at 
5 years in 354 patients with large posterior UM treated 
with median apex dose of 80 Gy. The lower enucleation 
rate in our study might be explained by higher radiation 
dose to the base of the tumors and less median tumor 
thickness. The median base dose in our cases was 1306 Gy, 
which is three times more radiation than scleral dose of 
patients treated with 125I plaques in Shields, study [26]. It 
is of interest that none of our patients developed scler-
al necrosis, reported in 1% [36] of patients following 
brachytherapy. This could be explained, by either a lower 
number of ciliochoroidal tumors, a known risk factor for 
scleral necrosis, or the short follow-up time in our cases.
The median apex dose rate in our patients was 
0.37 Gy/h, which is less than the American Brachyther-
apy Society recommended dose rate of 0.60-1.05 Gy/h. 
In contrast to Quivey et al. [37] who reported that a dose 
rate of less than 0.50 Gy/h could be associated with 
a 4.75 fold increase in local failure using 125I, we did not 
find any statistical difference between preserved and 
enucleated eyes regarding the apex dose rate. This may 
be due to small numbers of events (enucleation) in our 
study or more radiation dose to the base of tumors.
Poor visual function (VA ≤ 20/200) was evident in 
31.9%, 57.4%, and 61.7% of cases at 2, 5, and 10 years 
follow-up, respectively. In a large analysis of 579 pa-
tients with posterior UM of all sizes treated with 106Ru 
brachytherapy by Bergman et al. [14], poor visual acuity 
at 2, 5, and 10 years was reported in 32.5%, 39.2%, and 
44.8% of the patients. The higher rate of vision loss in our 
patients could be explained by greater tumor thickness 
as well as higher radiation dose to the sclera. All patients 
in our study had thick tumors, however, only 9.5% of en-
rolled patients reported by Bergman et al. [14] had a tu-
mor thickness more than 7 mm. The importance of tumor 
thickness on ultimate final visual acuity after brachyther-
apy has been emphasized in multiple reports [38,39].
Table 5. Predictors of radiation maculopathy, radiation papillopathy, and radiation retinopathy in patients 
with thick choroidal melanoma (7 mm ≤ thickness < 11 mm) treated with 106Ru brachytherapy
Variable p value Hazard ratio 95% confidence interval
Predictors (radiation maculopathy)
Tumor thickness 0.032 0.28 0.088-0.899
Radiation dose at tumor apexa 0.005 1.83 1.001-3.402
Radiation dose rate at tumor apexb 0.016 1.04 1.008-1.085
Radiation dose rate at tumor baseb 0.041 1.40 1.007-2.430
Predictors (radiation papillopathy)
Radiation at tumor basec 0.006 0.80 0.683-0.939
Tumor shaped 0.004 4.45 1.609-12.327
Radiation dose rate at tumor apexb 0.027 1.03 1.004-1.067
Radiation dose rate at tumor baseb 0.040 1.04 0.103-1.931
Predictors (retinopathy)
Tumor locatione 0.047 3.39 1.018-11.285
Tumor thicknessf 0.019 0.55 0.331-0.907
Plaque shapeh 0.041 4.76 1.065-21.304
aRadiation dose (in Gy), bradiation dose rate (in Gy/hr), ctumor diameter (in mm), dmushroom vs. dome-shaped, echoroidal vs. ciliochoroidal, fmean tumor thickness 
(in mm), h COB vs. CCB vs. CGD
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Although the comparison of our results and other 
published outcomes regarding the VA is complicated 
because of differences in patient demographics, tumor 
characteristics, and radiation parameters, the percent-
age of our patients with a final vision of 20/200 or less is 
comparable to those of Shields et al. [26] and Kaiserman 
et al. [15].
Several studies have addressed UM recurrence fol-
lowing brachytherapy. Lommatzsch et al. [11] evaluated 
141 eyes with small, medium, and large UMs treated with 
106Ru brachytherapy and reported a cumulative 15-year 
tumor recurrence in 37% of patients. Wilson and Hunger-
ford reported a 5-year tumor recurrence of 4%, 11%, and 
5% following 125I brachytherapy, 106Ru brachytherapy, 
and proton beam radiotherapy, respectively. This is in ac-
cordance with an 11.8% and 13.7% recurrence rate at 5 and 
10 years in our patients.
Neovascular glaucoma is not uncommon after ra-
diotherapy for large UM. We detected early (less than 
6 months post-operation) NVI without NVG in 7.8% of 
patients with thick UM. All of these patients developed 
total exudative retinal detachment immediately following 
brachytherapy. Neovascularization of the iris was treated 
with single or multiple intravitreal bevacizumab injec-
tions. The incidence of late neovascular glaucoma (de-
veloped after 6 months) was 3.9% during the first 5 years 
of follow-up. This complication was successfully treated 
with intravitreal bevacizumab injections and medication 
in the majority of cases.
Lower complications rate in our series of thick UMs 
may be a result of a lower radiation dose of apex and/
or a possible selection bias due to a tendency to enucleate 
very thick tumors. Therefore, tumors with a greater chance 
of receiving higher radiation and developing radiation- 
related complications were enucleated before entering our 
study. Also, the small sample size and retrospective nature 
of the study may limit generalization of our conclusions.
Conclusions
In summary, 106Ru brachytherapy is a successful alter-
native for enucleation for thick uveal melanoma. Lower 
doses of radiation to tumor apex, provided that enough 
radiation doses is delivered to the sclera, can successfully 
treat the tumors possibly because of the effects of radi-
ation on tumor blood supply. Randomized prospective 
studies are warranted to find the optimum 106Ru plaque 
radiation dose and dose rate balancing local tumor con-
trol and radiation complications.
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